【摘要】 目的初步探讨mTOR抑制剂Temsirolimus联合阿霉素对肝癌细胞的抗肿瘤作用机制及化疗增敏作用。方法体外培养肝癌细胞,取增殖期细胞进行实验,用MTT法检测单用Temsirolimus、阿霉素以及两者联合应用时对肿瘤细胞生长的影响,用流式细胞术检测细胞凋亡情况。结果在体外肝癌细胞株PLC/PRF/5、BEL7402、HuH7中,与单独用药相比,Temsirolimus联合阿霉素提高了细胞增殖抑制率及凋亡率。Temsirolimus联合阿霉素的抗肿瘤作用高于将阿霉素浓度增加1倍时的抗肿瘤作用。结论联合应用mTOR抑制剂及阿霉素可以提高抗肿瘤作用,前者对化疗药物有一定的增敏效应,两者联合可以通过减少阿霉素的剂量来减轻不良反应,同时不降低药物效能,有临床应用的前景。更多还原

【Abstract】 Objective To investigate the synergistic sensitizing effect of the combination of temsirolimus, an mTOR inhibitor, and adriamycin on hepatocellular carcinoma(HCC) cells. Method HCC cells were cultured in vitro, cells in proliferation phase were collected, MTT assay was used to determine the effect of temsirolimus alone, adriamycin alone,and their combination, besides, cell apoptosis was examined using flow cytometry. Result Temsirolimus plus adriamycin showed an enhanced inhibitory effect on cell proliferation and cell apoptosis rate compared to temsirolimus or adriamycin alone in HCC cells PLC/PRF/5, BEL7402, and Hu H7 in vitro. We also observed that the anti-tumor effect of temsirolimus combined with adriamycin was higher than adriamycin alone at doubled concentrations. Conclusion Temsirolimus plus adriamycin exhibits an enhanced anti-tumor effect in HCC, the combined therapy may reduce potential adverse reactions by trimming the dose of adriamycin, without compromised efficacy, suggesting a promising value in the clinical treatment of HCC.更多还原